Base de dados : MEDLINE
Pesquisa : D03.633.100.786.830.666 [Categoria DeCS]
Referências encontradas : 735 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 74 ir para página                         

  1 / 735 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27231098
[Au] Autor:Deepakumari HN; Jayanna BK; Prashanth MK; Revanasiddappa HD; Veeresh B
[Ad] Endereço:Department of Chemistry, Bharathi College, Bharathinagara, Mandya, Karnataka, India.
[Ti] Título:Synthesis and Anticonvulsant Activity of N-(Substituted)-1-methyl-2,4-dioxo-1,2-dihydroquinazoline-3(4H)-carboxamides.
[So] Source:Arch Pharm (Weinheim);349(7):566-71, 2016 Jul.
[Is] ISSN:1521-4184
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:A series of new N-(substituted)-1-methyl-2,4-dioxo-1,2-dihydroquinazoline-3(4H)-carboxamides were designed, synthesized, and evaluated for their anticonvulsant activity. Most of the synthesized compounds exhibited potent anticonvulsant activities in the maximal electroshock (MES) and pentylenetetrazol (PTZ) test. The most promising compound 4c showed significant anticonvulsant activity with a protective index value of 3.58. The compounds 4a-c were also found to have encouraging anticonvulsant activity in the MES and PTZ screen when compared with the standard drugs, valproate and methaqualone. The same compounds were found to exhibit advanced anticonvulsant activity as well as lower neurotoxicity than the reference drugs.
[Mh] Termos MeSH primário: Anticonvulsivantes/síntese química
Anticonvulsivantes/uso terapêutico
Quinazolinas/síntese química
Quinazolinas/uso terapêutico
Convulsões/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Eletrochoque
Metaqualona/uso terapêutico
Camundongos
Pentilenotetrazol
Picrotoxina/uso terapêutico
Convulsões/induzido quimicamente
Relação Estrutura-Atividade
Ácido Valproico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Quinazolines); 124-87-8 (Picrotoxin); 614OI1Z5WI (Valproic Acid); 7ZKH8MQW6T (Methaqualone); WM5Z385K7T (Pentylenetetrazole)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160528
[St] Status:MEDLINE
[do] DOI:10.1002/ardp.201600024


  2 / 735 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26316220
[Au] Autor:Stephens TT; Gardner D; Jones K; Sifunda S; Braithwaite R; Smith SE
[Ad] Endereço:Department of Psychology, Clark Atlanta University, Atlanta, Georgia, USA tstephensphd@gmail.com.
[Ti] Título:Correlates of Mandrax use and condom beliefs in preventing sexually transmitted infections among a cohort of South African prison inmates.
[So] Source:Int Health;8(2):142-7, 2016 Mar.
[Is] ISSN:1876-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study was designed to identify the extent to which self-reported Mandrax use impacts condom-use beliefs amongst South African prison inmates. METHODS: Participants were inmates from four prisons in the provinces of KwaZulu-Natal and Mpumalanga. In total, 357 inmates participated in the parent study of which 121 are included in this analysis based on their self-reported use of Mandrax. The questionnaire was developed in English, translated into Zulu, and back translated into English. Age significantly predicted the use of Mandrax: younger prison inmates reported higher use. Linear regression analysis was conducted to determine whether the use of Mandrax was associated with length of incarceration and other demographic variables, as well as participants' self-reported condom use beliefs behavior. RESULTS: Regression results indicated that two factors operationalizing condom-use beliefs were impacted by Mandrax use: 1) it is important to use condoms every time you have sex (p<0.01); 2) condoms work well to prevent the spread of HIV (p<0.02). Both factors were also inversely related to Mandrax use. CONCLUSION: STI prevention programs among prison inmates that seek to promote safer sex behaviors among men must address attitudes to condom use, specifically consistent and correct use of latex condoms and reducing substance misuse.
[Mh] Termos MeSH primário: Preservativos/utilização
Difenidramina/administração & dosagem
Metaqualona/administração & dosagem
Prisioneiros/psicologia
Doenças Sexualmente Transmissíveis/prevenção & controle
Transtornos Relacionados ao Uso de Substâncias/psicologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Combinação de Medicamentos
Conhecimentos, Atitudes e Prática em Saúde
Seres Humanos
Masculino
Prisões
Fatores Socioeconômicos
África do Sul
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
Inquéritos e Questionários
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Drug Combinations); 7ZKH8MQW6T (Methaqualone); 8076-99-1 (Mandrax); 8GTS82S83M (Diphenhydramine)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150829
[St] Status:MEDLINE
[do] DOI:10.1093/inthealth/ihv048


  3 / 735 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26056160
[Au] Autor:Hammer H; Bader BM; Ehnert C; Bundgaard C; Bunch L; Hoestgaard-Jensen K; Schroeder OH; Bastlund JF; Gramowski-Voß A; Jensen AA
[Ad] Endereço:Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (H.H., L.B., K.H.-J., A.A.J.); NeuroProof, Rostock, Germany (B.M.B., C.E., O.H.-U.S., A.G.-V.); and H. Lundbeck A/S, Valby, Denmark (C.B., J.F.B.).
[Ti] Título:A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude).
[So] Source:Mol Pharmacol;88(2):401-20, 2015 Aug.
[Is] ISSN:1521-0111
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the present study, we have elucidated the functional characteristics and mechanism of action of methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone, Quaalude), an infamous sedative-hypnotic and recreational drug from the 1960s-1970s. Methaqualone was demonstrated to be a positive allosteric modulator at human α1,2,3,5ß2,3γ2S GABAA receptors (GABAARs) expressed in Xenopus oocytes, whereas it displayed highly diverse functionalities at the α4,6ß1,2,3δ GABAAR subtypes, ranging from inactivity (α4ß1δ), through negative (α6ß1δ) or positive allosteric modulation (α4ß2δ, α6ß2,3δ), to superagonism (α4ß3δ). Methaqualone did not interact with the benzodiazepine, barbiturate, or neurosteroid binding sites in the GABAAR. Instead, the compound is proposed to act through the transmembrane ß((+))/α((-)) subunit interface of the receptor, possibly targeting a site overlapping with that of the general anesthetic etomidate. The negligible activities displayed by methaqualone at numerous neurotransmitter receptors and transporters in an elaborate screening for additional putative central nervous system (CNS) targets suggest that it is a selective GABAAR modulator. The mode of action of methaqualone was further investigated in multichannel recordings from primary frontal cortex networks, where the overall activity changes induced by the compound at 1-100 µM concentrations were quite similar to those mediated by other CNS depressants. Finally, the free methaqualone concentrations in the mouse brain arising from doses producing significant in vivo effects in assays for locomotion and anticonvulsant activity correlated fairly well with its potencies as a modulator at the recombinant GABAARs. Hence, we propose that the multifaceted functional properties exhibited by methaqualone at GABAARs give rise to its effects as a therapeutic and recreational drug.
[Mh] Termos MeSH primário: Encéfalo/efeitos dos fármacos
Hipnóticos e Sedativos/farmacologia
Metaqualona/farmacologia
Receptores de GABA-A/genética
Receptores de GABA-A/metabolismo
[Mh] Termos MeSH secundário: Animais
Sítios de Ligação
Seres Humanos
Locomoção/efeitos dos fármacos
Masculino
Camundongos
Mutação
Receptores de GABA-A/química
Drogas Ilícitas
Xenopus/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 0 (Receptors, GABA-A); 0 (Street Drugs); 7ZKH8MQW6T (Methaqualone)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150610
[St] Status:MEDLINE
[do] DOI:10.1124/mol.115.099291


  4 / 735 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24768639
[Au] Autor:Inoue K; Ochi A; Koda A; Wako Y; Kawasako K; Doi T
[Ad] Endereço:Maruho Co., Ltd., 93 Awata-cho, Chudoji, Shimogyo-ku, Kyoto 600-8815, Japan. Electronic address: inoue_czo@mii.maruho.co.jp.
[Ti] Título:The 14-day repeated dose liver micronucleus test with methapyrilene hydrochloride using young adult rats.
[So] Source:Mutat Res Genet Toxicol Environ Mutagen;780-781:123-7, 2015 Mar.
[Is] ISSN:1879-3592
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The repeated dose liver micronucleus (RDLMN) assay using young adult rats has the potential to detect genotoxic hepatocarcinogens that can be integrated into a general toxicity study. The assay methods were thoroughly validated by 19 Japanese facilities. Methapyrilene hydrochloride (MP), known to be a non-genotoxic hepatocarcinogen, was examined in the present study. MP was dosed orally at 10, 30 and 100mg/kg/day to 6-week-old male Crl:CD (SD) rats daily for 14 days. Treatment with MP resulted in an increase in micronucleated hepatocytes (MNHEPs) with a dosage of only 100mg/kg/day. At this dose level, cytotoxicity followed by regenerative cell growth was noted in the liver. These findings suggest that MP may induce clastogenic effects indirectly on the liver or hepatotoxicity of MP followed by regeneration may cause increase in spontaneous incidence of MNHEPs.
[Mh] Termos MeSH primário: Carcinógenos/toxicidade
Hepatócitos/efeitos dos fármacos
Fígado/efeitos dos fármacos
Metaqualona/toxicidade
Testes para Micronúcleos
[Mh] Termos MeSH secundário: Administração Oral
Fatores Etários
Animais
Peso Corporal/efeitos dos fármacos
Medula Óssea/efeitos dos fármacos
Aberrações Cromossômicas/efeitos dos fármacos
Comportamento Cooperativo
Relação Dose-Resposta a Droga
Esquema de Medicação
Hepatócitos/patologia
Seres Humanos
Japão
Fígado/patologia
Masculino
Especificidade de Órgãos
Ratos
Ratos Sprague-Dawley
Reticulócitos/efeitos dos fármacos
Sociedades Farmacêuticas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Carcinogens); 7ZKH8MQW6T (Methaqualone)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:150420
[Lr] Data última revisão:
150420
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140429
[St] Status:MEDLINE


  5 / 735 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23317403
[Au] Autor:Kostapanos MS; Rizos EC; Papanas N; Maltezos E; Elisaf MS
[Ad] Endereço:Department of Internal Medicine, Medical School, University of Ioannina, 451 10 Ioannina, Greece.
[Ti] Título:Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias.
[So] Source:Curr Pharm Des;19(17):3150-60, 2013.
[Is] ISSN:1873-4286
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Current lipid-lowering drugs are often unable to achieve low density lipoprotein cholesterol (LDL-C) goals. Moreover, despite LDL-C lowering mostly by statins, a considerable residual vascular risk remains. This is partly associated with atherogenic dyslipidemia where apolipoprotein (apo) B-containing lipoproteins predominate. Mitochondrial Triglyceride (TG) transfer protein (MTP) is a key enzyme for apoB-containing lipoprotein assembly and secretion. This is mostly attributed to its capacity to transfer lipid components (TGs, cholesterol esters and phospholipids) to the endoplasmic reticulum lumen, where these lipoproteins are assembled. Several agents were developed to inhibit MTP wherever it is expressed, namely the liver and/or the intestine. Liver-specific MTP inhibitors reduce secretion of very low density lipoproteins (VLDL) mostly containing apoB100, while the intestine-specific ones reduce secretion of chylomicrons containing apoB48. These drugs can significantly reduce total cholesterol, LDL-C, TGs, VLDL cholesterol, as well as apoB levels in vivo. They may also exert anti-atherosclerotic and insulin-sensitizing effects. Limited clinical data suggest that these compounds can also improve the serum lipid profile in patients with homozygous familial hypercholesterolemia (HoFH). The accumulation of unsecreted fat in the liver and intestinal lumen is associated with elevation of aminotransferases and steatorrhea. Liver steatosis can be avoided by the use of intestine-specific MTP inhibitors, while steatorrhea by low-fat diet. Future indications for these developing drugs may include dyslipidemia associated with insulin resistant states, familial combined hyperlipidemia and HoFH. Future clinical trials are warranted to assess the efficacy and safety of MTP inhibitors in various clinical states.
[Mh] Termos MeSH primário: Proteínas de Transporte/antagonistas & inibidores
Dislipidemias/tratamento farmacológico
Hipolipemiantes/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Apolipoproteínas B/metabolismo
Benzamidas/farmacologia
Benzamidas/uso terapêutico
Benzimidazóis/farmacologia
Benzimidazóis/uso terapêutico
Proteínas de Transporte/fisiologia
Flavanonas/farmacologia
Flavanonas/uso terapêutico
Seres Humanos
Malonatos/farmacologia
Malonatos/uso terapêutico
Metaqualona/análogos & derivados
Metaqualona/farmacologia
Metaqualona/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (4'-bromo-3'-methylmethaqualone); 0 (Apolipoproteins B); 0 (BMS201038); 0 (Benzamides); 0 (Benzimidazoles); 0 (Carrier Proteins); 0 (Flavanones); 0 (Hypolipidemic Agents); 0 (Malonates); 0 (diethyl 2-((3-dimethylcarbamoyl-4-((4'-trifluoromethylbiphenyl-2-carbonyl)amino)phenyl)acetyloxymethyl)-2-phenylmalonate); 0 (microsomal triglyceride transfer protein); 7ZKH8MQW6T (Methaqualone); HN5425SBF2 (naringenin)
[Em] Mês de entrada:1311
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130116
[St] Status:MEDLINE


  6 / 735 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23298217
[Au] Autor:Ceschi A; Giardelli G; Müller DM; Elavumkudy S; Manini AF; Rauber-Lüthy C; Hofer KE
[Ad] Endereço:Swiss Toxicological Information Centre, Associated Institute of the University of Zurich, Zurich, Switzerland. Alessandro.Ceschi.@usz.ch
[Ti] Título:Acute neurotoxicity associated with recreational use of methylmethaqualone confirmed by liquid chromatography tandem mass spectrometry.
[So] Source:Clin Toxicol (Phila);51(1):54-7, 2013 Jan.
[Is] ISSN:1556-9519
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Methylmethaqualone is a sedative designer drug created by adding a methyl group to the 3-phenyl ring of methaqualone, and is at present not subject to restrictive regulation in many countries. To our knowledge, no case of methylmethaqualone abuse has been published to date in the scientific literature, and the only sources of information are users' reports on Web discussion forums and data from preclinical animal studies. We report a case of oral methylmethaqualone abuse confirmed by liquid chromatography tandem mass spectrometry in a 24-year-old previously healthy Caucasian male. Observed symptoms and signs such as central nervous system depression alternating with excitation, psychomotor agitation, muscle hyperactivity, and tachycardia were compatible with methaqualone-induced adverse effects. Except for the mild tachycardia (115 beats/min), other vital signs were normal: blood pressure 134/89 mmHg, body temperature 36.2°C (97.16°F), and peripheral oxygen saturation 99% while breathing room air. The ECG showed no prolongation of the QT interval and the QRS duration was normal. Laboratory analysis revealed a slight increase in creatine kinase (368 U/L) and alanine aminotransferase (90 U/L) serum concentrations. Blood alcohol concentration was 0.32 g/L. Methylmethaqualone was identified in a serum sample collected on admission which was analyzed by a liquid chromatography tandem mass spectrometry toxicological screening method using turbulent flow online extraction. After a few days the patient ingested the same amount of substance with identical symptoms. Based on the chemical structure and animal data, and according to this case report and users' Web reports, methylmethaqualone appears to have a similar acute toxicity profile to methaqualone, with marked psychomotor stimulation. Symptoms of acute toxicity can be expected to resolve with supportive care.
[Mh] Termos MeSH primário: Drogas Desenhadas/toxicidade
Hipnóticos e Sedativos/toxicidade
Metaqualona/análogos & derivados
Síndromes Neurotóxicas/sangue
[Mh] Termos MeSH secundário: Adulto
Cromatografia Líquida de Alta Pressão
Drogas Desenhadas/análise
Drogas Desenhadas/farmacocinética
Seres Humanos
Hipnóticos e Sedativos/sangue
Hipnóticos e Sedativos/farmacocinética
Masculino
Metaqualona/sangue
Metaqualona/farmacocinética
Metaqualona/toxicidade
Metilação
Síndromes Neurotóxicas/fisiopatologia
Síndromes Neurotóxicas/terapia
Índice de Gravidade de Doença
Espectrometria de Massas em Tandem
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3-(2,4-dimethylphenyl)-2-methylquinazolin-4(3H)-one); 0 (Designer Drugs); 0 (Hypnotics and Sedatives); 7ZKH8MQW6T (Methaqualone)
[Em] Mês de entrada:1303
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:130110
[St] Status:MEDLINE
[do] DOI:10.3109/15563650.2012.758855


  7 / 735 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22137344
[Au] Autor:El-Azab AS; Eltahir KE
[Ad] Endereço:Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. adelazaba@yahoo.com
[Ti] Título:Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives.
[So] Source:Bioorg Med Chem Lett;22(1):327-33, 2012 Jan 01.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A new series of 2,3,8-trisubstituted-4(3H)-quinazoline derivatives were synthesized, evaluated for their anticonvulsant activity against electrically (MES) and chemically (PTZ, picrotoxin and Strychnine) induced seizures and compared with the standard drugs methaqualone and sodium valproate. Compounds 3, 17 and 22 proved to be the most potent compounds of this series with relatively low neurotoxicity and low toxicity in the median lethal dose test as compared with the reference drugs. The obtained results showed that the most active compounds could be useful as a template for future design, modification and investigation to produce more active analogs.
[Mh] Termos MeSH primário: Anticonvulsivantes/farmacologia
Química Farmacêutica/métodos
Quinazolinas/farmacologia
Convulsões/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Desenho de Drogas
Seres Humanos
Masculino
Metaqualona/farmacologia
Camundongos
Modelos Químicos
Sistema Nervoso/efeitos dos fármacos
Ácido Valproico/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Quinazolines); 614OI1Z5WI (Valproic Acid); 7ZKH8MQW6T (Methaqualone)
[Em] Mês de entrada:1208
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111206
[St] Status:MEDLINE
[do] DOI:10.1016/j.bmcl.2011.11.007


  8 / 735 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22019312
[Au] Autor:Verma R; Tiwari N
[Ti] Título:Phenytoin intoxication induced by Mandrax (methaqualone).
[So] Source:Epilepsy Res;98(2-3):281-2, 2012 Feb.
[Is] ISSN:1872-6844
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticonvulsivantes/efeitos adversos
Doenças Cerebelares/induzido quimicamente
Difenidramina/efeitos adversos
Metaqualona/efeitos adversos
Fenitoína/efeitos adversos
Doenças do Nervo Vestibulococlear/induzido quimicamente
[Mh] Termos MeSH secundário: Doenças Cerebelares/complicações
Combinação de Medicamentos
Epilepsia/tratamento farmacológico
Seres Humanos
Masculino
Doenças do Nervo Vestibulococlear/complicações
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Drug Combinations); 6158TKW0C5 (Phenytoin); 7ZKH8MQW6T (Methaqualone); 8076-99-1 (Mandrax); 8GTS82S83M (Diphenhydramine)
[Em] Mês de entrada:1205
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111025
[St] Status:MEDLINE
[do] DOI:10.1016/j.eplepsyres.2011.10.004


  9 / 735 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22035715
[Au] Autor:Herzberg D
[Ad] Endereço:SUNY-University at Buffalo, History Department, 546 Park Hall, North Campus, Buffalo, NY 14260, USA. herzberg@buffalo.edu
[Ti] Título:Blockbusters and controlled substances: Miltown, Quaalude, and consumer demand for drugs in postwar America.
[So] Source:Stud Hist Philos Biol Biomed Sci;42(4):415-26, 2011 Dec.
[Is] ISSN:1879-2499
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In 1955 Carter Products launched its new tranquilizer Miltown with a huge marketing blitz; Miltown soon became one of America's earliest "blockbuster" celebrity drugs. In 1981, federal agents shut down a network of "stress clinics" and arrested the owners, medical staff, and other personnel for illegally trafficking in the sedative Quaalude; Quaalude soon became a "Schedule I Controlled Substance." Both of these stories are familiar, indeed archetypal, moments from America's postwar medical system. As the Miltown example reminds us, this fundamentally commercial system was built on the creation and courting of consumer demand for medical products and services, particularly drugs. As the Quaalude example shows, however, this system also incorporated tools for reining in excessive consumer demand. Together the two episodes affirm an enduring irony of the American medical system: the need for regulatory campaigns to tame lively markets for drugs that had become popular, in part, because of advertising campaigns. This article uses the Miltown and Quaalude sagas to explore the issue of consumer demand for prescription medicines, arguing that efforts to stoke or quash that demand have shaped (and linked) America's medical system and its drug control regimes.
[Mh] Termos MeSH primário: Indústria Farmacêutica/história
Necessidades e Demandas de Serviços de Saúde/história
Hipnóticos e Sedativos/história
Legislação de Medicamentos
Marketing/história
Meprobamato/história
Metaqualona/história
[Mh] Termos MeSH secundário: Instituições de Assistência Ambulatorial/história
Instituições de Assistência Ambulatorial/legislação & jurisprudência
Indústria Farmacêutica/ética
Indústria Farmacêutica/legislação & jurisprudência
Necessidades e Demandas de Serviços de Saúde/legislação & jurisprudência
História do Século XX
Seres Humanos
Marketing/legislação & jurisprudência
Medicamentos sob Prescrição/história
Estresse Psicológico/tratamento farmacológico
Estresse Psicológico/história
Estados Unidos
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 0 (Prescription Drugs); 7ZKH8MQW6T (Methaqualone); 9I7LNY769Q (Meprobamate)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111101
[St] Status:MEDLINE
[do] DOI:10.1016/j.shpsc.2011.05.005


  10 / 735 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:16861151
[Au] Autor:Gillman MA; Harker N; Lichtigfeld FJ
[Ad] Endereço:South African Brain Research Institute, Johannesburg, South Africa. mag@iafrica.com
[Ti] Título:Combined cannabis/methaqualone withdrawal treated with psychotropic analgesic nitrous oxide.
[So] Source:Int J Neurosci;116(7):859-69, 2006 Jul.
[Is] ISSN:0020-7454
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This article reports the first single-blind study using psychotropic analgesic nitrous oxide (PAN) for treating acute withdrawal states following the abuse of methaqualone combined and smoked with cannabis. Smoked methaqualone combined with cannabis is called "white pipe" (WP). South Africa is the only country in the world where WP is a major form of substance abuse. This article demonstrates in 101 consecutively treated patients given placebo (100% oxygen) followed by PAN that this therapy produced a measurable therapeutic effect (more than 50% improvement) in 87 patients. This study confirms that WP is a form of substance abuse confined mainly to young adult male subjects.
[Mh] Termos MeSH primário: Cannabis/efeitos adversos
Metaqualona/efeitos adversos
Óxido Nitroso/administração & dosagem
Psicotrópicos/administração & dosagem
Síndrome de Abstinência a Substâncias/etiologia
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Hipnóticos e Sedativos
Masculino
Meia-Idade
Avaliação de Resultados (Cuidados de Saúde)/métodos
Método Simples-Cego
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 0 (Psychotropic Drugs); 7ZKH8MQW6T (Methaqualone); K50XQU1029 (Nitrous Oxide)
[Em] Mês de entrada:0609
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060725
[St] Status:MEDLINE



página 1 de 74 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde